Metastatic Cancer - Pipeline Review, H2 2012


#138128

686pages

Global Markets Direct

$ 2500

In Stock


Metastatic Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Metastatic Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Cancer. 

Metastatic Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Cancer.
  • A review of the Metastatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Cancer pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 20
List of Figures 24
Introduction 25
Global Markets Direct Report Coverage 25
Metastatic Cancer Overview 26
Therapeutics Development 27
An Overview of Pipeline Products for Metastatic Cancer 27
Metastatic Cancer Therapeutics under Development by Companies 29
Metastatic Cancer Therapeutics under Investigation by Universities/Institutes 43
Metastatic Cancer Therapeutics Products under Development by Companies 67
Metastatic Cancer Therapeutics Products under Investigation by Universities/Institutes 97
Companies Involved in Metastatic Cancer Therapeutics Development 150
Bristol-Myers Squibb Company 150
Johnson & Johnson 151
Boehringer Ingelheim GmbH 152
F. Hoffmann-La Roche Ltd. 153
Kyowa Hakko Kirin Co., Ltd. 154
Celsion Corporation 155
Abbott Laboratories 156
Vical Incorporated 157
Amgen Inc. 158
Sanofi-Aventis 159
Adherex Technologies Inc. 160
AstraZeneca PLC 161
Eli Lilly and Company 162
Viralytics Ltd. 163
GlaxoSmithKline plc 164
Tekmira Pharmaceuticals Corp. 165
Bionovo, Inc. 223
Cytokinetics, Inc 224
Telik, Inc. 225
Regeneron Pharmaceuticals, Inc. 226
Array BioPharma Inc. 227
Transgene SA 228
Progen Pharmaceuticals Limited 229
Green Cross Corporation 230
Hanall Pharmaceutical Co., Ltd. 231
Cytos Biotechnology AG 232
Pro-Pharmaceuticals, Inc. 233
Jiangsu Hengrui Medicine Co., Ltd. 234
Threshold Pharmaceuticals, Inc. 235
Provectus Pharmaceuticals, Inc. 236
Galapagos NV 237
Summit Corporation plc 238
BioAlliance Pharma SA 239
Natco Pharma Limited 240
Nang Kuang Pharmaceutical Co., Ltd. 241
Transgene Biotek Ltd 242
e-Therapeutics plc 243
Rexahn Pharmaceuticals, Inc. 244
Merrion Pharmaceuticals Plc 245
MabVax Therapeutics, Inc. 246
Morphotek, Inc. 247
Digna Biotech, S.L. 248
Angelini Group 249
Debiopharm Group 250
Wilex AG 251
INSYS Therapeutics, Inc. 252
Supratek Pharma Inc. 253
DNA Therapeutics S.A. 254
Meabco A/S 255
Biotecnol SA 256
Aragon Pharmaceuticals, Inc. 301
BioLife Science Forschungs- und Entwicklungsges. m. b. H. 302
Cytavis Biopharma GmbH 303
Mayo Clinic 304
Faron Pharmaceuticals, Ltd. 305
Polaris Group 306
Agennix AG 307
EirGen Pharma Ltd. 308
Gradalis Inc. 309
Immunovative Therapies, Ltd. 310
Lipotek Pty Ltd 311
Metastatic Cancer Therapeutics Assessment 312
Assessment by Monotherapy Products 312
Assessment by Combination Products 313
Drug Profiles 314
eribulin mesylate - Drug Profile 314
Product Description 314
Mechanism of Action 314
R&D Progress 314
ARQ 197 + Erlotinib - Drug Profile 360
Product Description 360
Mechanism of Action 360
R&D Progress 360
FEC Chemotherapy + Docetaxel - Drug Profile 362
Product Description 362
Mechanism of Action 362
R&D Progress 362
FEC Chemotherapy + DG Chemotherapy - Drug Profile 364
Product Description 364
Mechanism of Action 364
R&D Progress 365
fulvestrant - Drug Profile 366
Product Description 366
Mechanism of Action 366
R&D Progress 366
Fulvestrant + Exemestane + Anastrozole + Letrozole - Drug Profile 367
Product Description 367
Mechanism of Action 367
R&D Progress 368
Fulvestrant + Lapatinib - Drug Profile 369
Product Description 369
Mechanism of Action 369
R&D Progress 369
Aldesleukin + Vaccine Therapy - Drug Profile 371
Product Description 371
Mechanism of Action 371
R&D Progress 371
Faslodex + Arimidex - Drug Profile 373
Product Description 373
Mechanism of Action 373
R&D Progress 373
R435 + Paclitaxel - Drug Profile 419
Product Description 419
Mechanism of Action 419
R&D Progress 419
TH-302 + Doxorubicin - Drug Profile 435
Product Description 435
Mechanism of Action 435
R&D Progress 435
Avastin + Taxane - Drug Profile 437
Product Description 437
Mechanism of Action 437
R&D Progress 437
Zoledronic Acid - Drug Profile 439
Product Description 439
Mechanism of Action 439
R&D Progress 439
trastuzumab - Drug Profile 440
Product Description 440
Mechanism of Action 440
R&D Progress 440
Aflibercept + Docetaxel + Prednisone - Drug Profile 468
Product Description 468
Mechanism of Action 468
R&D Progress 468
IMC-1121B + Docetaxel - Drug Profile 480
Product Description 480
Mechanism of Action 480
R&D Progress 480
Ixempra - Drug Profile 482
Product Description 482
Mechanism of Action 482
R&D Progress 482
Research and Development Brief 482
cabazitaxel - Drug Profile 483
Product Description 483
Mechanism of Action 483
R&D Progress 483
Lapatinib + Trastuzumab + Anastrozole - Drug Profile 484
Product Description 484
Mechanism of Action 484
R&D Progress 484
Lapatinib + Trastuzumab + Exemestane - Drug Profile 486
Product Description 486
Mechanism of Action 486
R&D Progress 486
tegafur - Drug Profile 488
Product Description 488
Mechanism of Action 488
R&D Progress 488
Doxorubicin + Docetaxel - Drug Profile 489
Product Description 489
Mechanism of Action 489
R&D Progress 489
Doxorubicin + Paclitaxel - Drug Profile 490
Product Description 490
Mechanism of Action 490
R&D Progress 490
AntiAndrogen Therapy + Goserelin + Docetaxel - Drug Profile 501
Product Description 501
Mechanism of Action 501
R&D Progress 501
Fluorouracil + Leucovorin + Oxaliplatin + Irinotecan - Drug Profile 502
Product Description 502
Mechanism of Action 502
R&D Progress 503
Bevacizumab + Cyclophosphamide + Capecitabine - Drug Profile 504
Product Description 504
Mechanism of Action 504
R&D Progress 505
IMC-1121B + Paclitaxel - Drug Profile 509
Product Description 509
Mechanism of Action 509
R&D Progress 509
Aromasin + Entinostat - Drug Profile 510
Product Description 510
Mechanism of Action 510
R&D Progress 510
Avastin + Docetaxel - Drug Profile 511
Product Description 511
Mechanism of Action 511
R&D Progress 511
aflibercept - Drug Profile 512
Product Description 512
Mechanism of Action 512
R&D Progress 512
Phase II - Trial Details 513
RAD001 + Trastuzumab + Paclitaxel - Drug Profile 514
Product Description 514
Mechanism of Action 514
R&D Progress 514
Nexavar + Capecitabine - Drug Profile 516
Product Description 516
Mechanism of Action 516
R&D Progress 516
trastuzumab - Drug Profile 518
Product Description 518
Mechanism of Action 518
R&D Progress 518
Docetaxel + Pertuzumab + Trastuzumab - Drug Profile 519
Product Description 519
Mechanism of Action 519
R&D Progress 520
Bevacizumab + Exemestane - Drug Profile 521
Product Description 521
Mechanism of Action 521
R&D Progress 521
leuprolide acetate - Drug Profile 531
Product Description 531
Mechanism of Action 531
R&D Progress 531
Eir-070 - Drug Profile 532
Product Description 532
Mechanism of Action 532
R&D Progress 532
M-200 - Drug Profile 533
Product Description 533
Mechanism of Action 533
R&D Progress 533
Research and Development Brief 533
Metastatic Cancer Therapeutics Drug Profile Updates 535
Metastatic Cancer Therapeutics Discontinued Products 610
Metastatic Cancer Therapeutics - Dormant Products 623

Appendix 684
Methodology 684
Coverage 684
Secondary Research 684
Primary Research 684
Expert Panel Validation 684
Contact Us 685
Disclaimer 685

Number of Products Under Development for Metastatic Cancer, H2 2012 27
Products under Development for Metastatic Cancer Comparative Analysis, H2 2012 28
Number of Products under Development by Companies, H2 2012 30
Number of Products under Development by Companies, H2 2012 (Contd..1) 31
Number of Products under Development by Companies, H2 2012 (Contd..2) 32
Number of Products under Development by Companies, H2 2012 (Contd..3) 33
Number of Products under Development by Companies, H2 2012 (Contd..4) 34
Number of Products under Development by Companies, H2 2012 (Contd..5) 35
Number of Products under Development by Companies, H2 2012 (Contd..6) 36
Number of Products under Development by Companies, H2 2012 (Contd..7) 37
Number of Products under Development by Companies, H2 2012 (Contd..8) 38
Number of Products under Development by Companies, H2 2012 (Contd..9) 39
Number of Products under Development by Companies, H2 2012 (Contd..10) 40
Number of Products under Development by Companies, H2 2012 (Contd..11) 41
Number of Products under Development by Companies, H2 2012 (Contd..12) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 59
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 60
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 61
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 62
Comparative Analysis by Late Stage Development, H2 2012 63
Comparative Analysis by Mid Clinical Stage Development, H2 2012 64
Comparative Analysis by Early Clinical Stage Development, H2 2012 65
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 66
Products under Development by Companies, H2 2012 67
Products under Development by Companies, H2 2012 (Contd..1) 68
Products under Development by Companies, H2 2012 (Contd..2) 69
Products under Development by Companies, H2 2012 (Contd..3) 70
Products under Development by Companies, H2 2012 (Contd..4) 71
Products under Development by Companies, H2 2012 (Contd..5) 72
Products under Development by Companies, H2 2012 (Contd..6) 73
Products under Development by Companies, H2 2012 (Contd..7) 74
Products under Development by Companies, H2 2012 (Contd..8) 75
Products under Development by Companies, H2 2012 (Contd..9) 76
Products under Development by Companies, H2 2012 (Contd..10) 77
Products under Development by Companies, H2 2012 (Contd..11) 78
Products under Development by Companies, H2 2012 (Contd..12) 79
Products under Development by Companies, H2 2012 (Contd..13) 80
Products under Development by Companies, H2 2012 (Contd..14) 81
Products under Development by Companies, H2 2012 (Contd..15) 82
Products under Development by Companies, H2 2012 (Contd..16) 83
Products under Development by Companies, H2 2012 (Contd..17) 84
Products under Development by Companies, H2 2012 (Contd..18) 85
Products under Development by Companies, H2 2012 (Contd..19) 86
Products under Development by Companies, H2 2012 (Contd..20) 87
Products under Development by Companies, H2 2012 (Contd..21) 88
Products under Development by Companies, H2 2012 (Contd..22) 89
Products under Development by Companies, H2 2012 (Contd..23) 90
Products under Development by Companies, H2 2012 (Contd..24) 91
Products under Development by Companies, H2 2012 (Contd..25) 92
Products under Development by Companies, H2 2012 (Contd..26) 93
Products under Development by Companies, H2 2012 (Contd..27) 94
Products under Development by Companies, H2 2012 (Contd..28) 95
Products under Development by Companies, H2 2012 (Contd..29) 96
Products under Investigation by Universities/Institutes, H2 2012 97
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 98
Assessment by Monotherapy Products, H2 2012 312
Assessment by Combination Products, H2 2012 313
Metastatic Cancer Therapeutics Drug Profile Updates 535
Metastatic Cancer Therapeutics Discontinued Products 610
Metastatic Cancer Therapeutics Discontinued Products (Contd..1) 611
Metastatic Cancer Therapeutics Dormant Products 623
Metastatic Cancer Therapeutics Dormant Products (Contd..1) 624
Number of Products under Development for Metastatic Cancer, H2 2012 27
Products under Development for Metastatic Cancer Comparative Analysis, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 43
Assessment by Monotherapy Products, H2 2012 312
Assessment by Combination Products, H2 2012 313